Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5428029 multiple ascending dose study in healthy volunteers and chronic hepatitis C genotype 1 patients
NL-OMON36081Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RO5428029 in hepatitis C virus infection (4 arms), sponsored by Roche. Primary endpoints: Safety and tolerability, Pharmacokinetics of RO1080713 and 2 more. Started Sep 2011; status: active, not recruiting.
02
Drugs
RO5428029
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON36081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36081.